{"id":156173,"date":"2021-11-07T01:41:25","date_gmt":"2021-11-07T05:41:25","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/longeveron-selects-clinical-research-organization-for-phase-2-alzheimers-disease-trial\/"},"modified":"2024-08-18T11:43:22","modified_gmt":"2024-08-18T15:43:22","slug":"longeveron-selects-clinical-research-organization-for-phase-2-alzheimers-disease-trial","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/longeveron-selects-clinical-research-organization-for-phase-2-alzheimers-disease-trial.php","title":{"rendered":"Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer\u2019s Disease Trial"},"content":{"rendered":"<p><![CDATA[MIAMI, Nov.  05, 2021  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or \"Company\"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (\u201cBiorasi\u201d) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer\u2019s Disease (AD) subjects.]]><\/p>\n<p>View original post here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/11\/05\/2328522\/0\/en\/Longeveron-Selects-Clinical-Research-Organization-for-Phase-2-Alzheimer-s-Disease-Trial.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer\u2019s Disease Trial\">Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer\u2019s Disease Trial<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View original post here: Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer\u2019s Disease Trial <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/longeveron-selects-clinical-research-organization-for-phase-2-alzheimers-disease-trial.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156173","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156173"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156173"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156173\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}